biocept inc bioc buy pt under-valued oncolog test space initi coverag buy
appl inc hold pt video stream servic still work progress rais pt
sign stabil maintain hold analyst nehal chokshi full summari
intelgenx technolog corp igxt buy pt rizaport migrain pdufa near alzheim program non-
amyloid move forward pipelin progress analyst jason mccarthi ph full summari
bioscienc inc yten buy pt field test yield increas canola expect canola
commerci reiter buy analyst jame jang full summari
corpor event call maxim salesperson inform
inmun inc inmb cover mccarthi ndr nyc ceo dr rj tesi cfo david moss tue apr
stealthga inc gass cover jang ndr nyc ceo harri vafia tue
american resourc corpor arec ndr nyc ceo chairman board jensen fri
navig hold ltd nvg cover jang group luncheon new york ceo david butter wed apr
pm et
tuanch limit tc cover jang ndr nyc cfo troy mao investor relat dana cheng mon
tuanch limit tc cover jang ndr boston cfo troy mao investor relat dana cheng tue
tuanch limit tc cover jang ndr chicago cfo troy mao investor relat dana cheng
tuanch limit tc cover jang ndr san francisco cfo troy mao investor relat dana cheng
cover jang ndr boston ceo gari vogel cfo frank decostanzo
director strategi busi develop costa tsoutsoplid tue apr
maxim group industri confer nyc mygr host sullivan thu
corpor cover ndr milwauke evp cao cfo mark wolfing
svp financ robert verostek tue may
inc cover klee ndr nyc ceo steve picket cfo ahlstrom tue apr
inc cover klee ndr boston ceo steve picket cfo ahlstrom wed apr
inc cover klee ndr chicago ceo steve picket cfo ahlstrom thu apr
annual silicon valley bu tour host chokshi tue jul
video stream servic still work progress rais
pt sign stabil maintain hold
video stream servic valu like depend upon content
aggreg buy-in revamp tv app
prior survey data lead us still pin best-cas scenario attach rate
year servic in-lin expect
risk multi-year iphon instal base downsiz remain materi
assum pressur spread beyond china
take year re-siz china
rais ep estim price target multipl back
stabil assumpt thu price target
video stream servic valu like depend upon content aggreg
buy-in revamp tv app much-anticip video stream servic
unveil tv prove preview long-form video content
commiss nice summari content commiss price
reveal yet avail announc fall beyond origin content
commiss believ part valu tri creat
user enabl search artifici intellig learn user prefer
prime video hulu espn spectrum etc user paid access
tv app order valu materi user believ need
gain permiss content aggreg platform index content henc
believ enhanc tv app come avail first order time
build critic mass user incent aggreg access index
content content aggreg effect critic function
 nr add origin content exclus avail util
tv app level adopt new tv app amongst user
content aggreg allow index content like critic input
end consum access aapl commiss origin content
price point without content aggreg enabl tv app index
content expect user tv app limit
devic user ultim limit effect devic user
prior survey data lead us still pin best-cas scenario attach rate
year servic in-lin expect per downgrad note
may pin attach rate video subscript servic iphon
user instal base activ iphon fee note per
prior survey work achiev penetr iwork within iphon
instal base domin incumb microsoft offic believ
appropri parallel given domin incumb video stream
servic news subscript servic enhanc appl pay appl card
app store appl arcad in-lin prior expect lead us
remain comfort around key long-term assumpt servic
shown figur page chang make servic model
push-out video content subscript avail march quarter
septemb quarter result slightli lower
jun ep estim respect reduct
risk multi-year iphon instal base downsiz remain materi
assum pressur spread beyond china take
year re-siz china given new data point sinc dec
 earn call januari indic y/i trajectori iphon worsen
current y/i declin project back
prior content iphon revenu declin anoth asp
pressur anoth unit declin rais iphon
revenu estim y/i due asp pressur well
iphon gm estim thu ep estim
y/i note still see materi risk
face multi-year period iphon revenu declin longer greater
result either china iphon user base resiz take multipl year
grow unwilling user region emea japan north
america pay premium product
rais ep estim price target multipl back
stabil assumpt thu price target given
updat perspect like iphon revenu stabil follow
tough rais price target multipl back standard
util across coverag univers result rais
price target rais come higher multipl
remaind increas ep forecast result assum
iphon instal base resiz take year
click full note
under-valued oncolog test space
initi coverag buy rate pt
initi coverag biocept buy rate price target
biocept target selector liquid biopsi platform addit
provid action data base circul tumor dna ctdna analysi
incorpor circul tumor cell ctc analysi differenti
compani increasingli crowd liquid biopsi space
test cost-effect reimburs also attract
doctors/hospit may bill payer separ profession servic
creat revenu stream back provid decentr clia model
target selector next research use ruo kit may enabl
selector perform local point care
unlock valu bioinformat accumul bioinformat
data critic featur peer space like guardant health
gh nr market cap biocept partnership progno privat
announc aim leverag artifici intellig biocept
patient sampl build build data could attract
pharma/biotech compani biomark target therapi
conclus biocept potenti best-in-class liquid biopsi platform
cost- time-effect manag invest build target
selector platform busi model posit compani return
growth see upsid
liquid biopsi opportun biocept cost tissu biopsi run
highli invas target therapi molecular level
car-t checkpoint parp small molecul shift oncolog
treatment paradigm depend understand patient cancer
chang molecular level liquid biopsi use ctdna blood sampl
interrog genom level provid action data physician
drug develop differenti biocept target selector platform use ctdna
also whole cell test ctc allow physician choos individu
clinic relev test attract payer rather one-size-fits-al gene
panel target selector demonstr high concord tissu data across
valid biomark found nccn guidelin
biocept busi model incorpor tech compon profession
compon tcpc central clia lab util mani dx compani
classic model physician take blood sampl send central lab run
order panel assay interpret data provid report physician
tcpc use empowertc tech-onli servic biocept run technic part
liquid biopsi data made avail via cloud portal physician
integr physician clinic/hospit pathologist test
profession compon addit enabl physician make his/her
data interpret also allow bill payer separ provid revenu
stream provid well biocept separ liquid biopsi space
biocept first compani knowledg use approach
compel valuat model revenu target selector test use ctdna
us appli risk adjust project test revenu
base commercialization/adopt risk capit need support commerci growth
factor appli discount rate discount ep sum
part model equal rate deriv price target
click full note
field test yield increas canola expect
canola commerci reiter buy
post result yesterday close report posit field
test data harvest
yten report seed yield increas canola expect
field test possibl commerci
yten rais net fess direct offer issu share
per share proce use work capit need relat
base anticip cash burn
expect equiti offer year-end
hit mileston reiter buy rate
financi result mix yten continu hit field test
revenu vs maxim consensu
ebitda loss vs maxim consensu
oper loss vs maxim consensu
harvest result canola encourag yten announc
field test canola show seed yield increas best
line base test yten plan continu commerci develop
phase includ addit field test canada
canola king expect yten progress corn soybean
camelina follow although yten concurr work develop novel gene
trait cash crop near-term focu canola due string posit
test under-invest ag major due focu corn soybean
partnership help push forward develop corn soybean
ag major focu corn soybean enabl yten expand
exist partnership enhanc gene trait current research
partnership bayer/monsanto bayri nr develop
soybean work forag genet subsidiari lake privat
sorghum expect cross-research partnership help yten pull forward
addit cash infus need march yten rais
net fee direct offer issu share per share
anticip anoth capit rais end estim cash
burn low end compani guidanc base
expect yten execut equiti rais soon expect compani
tap capit market lieu debt compani maintain clean balanc
compel valuat yten earli stage develop compani expect
commerci seed busi commenc partnership
lead ag seed compani price target deriv util
dcf methodolog assum perpetu growth rate wacc
click full note
onconova announc surpass enrol mark
mimet intraven high-risk myelodysplast syndrom hr-md
complet enrol expect
pivot phase
inspir overal surviv endpoint requir event patient
death complet studi given patient enrol
high risk md life expect month averag
possibl event could reach enrol complet
view
onconova pipelin also make progress includ oral rigosertib
md rigosertib lung cancer rasopathi
multi-cent random studi evalu iv rigosertib ra mimet
patient age high risk md fail hma therapi
within month cycl design base previou on-tim studi patient
random ratio two treatment arm iv rigosertib plu best support
versu physician choic plu best support primari endpoint
overal surviv trial enrol complet enrol expect
could see top-line well death like risk/reward
inspir outcom view around trial paramet progress
chang data readout signific catalyst ontx share view
first line md oral rigosertib combo readi describ dr lewi
silverman import contributor develop azacytidin aza standard
care remain hypomethyl agent hma aza decitabin respons rate
cr/pr/mcr high risk md hma alon combin
lenalidomid vorinostat signific improv respons rate
rigosertib aza hma nave hma failur respect
includ cr pr cr pr patient transfus independ
reduc blast bone marrow recoveri improv qol essenti
patient fail hma secondari md therapeut option front line md
increas respons rate hma oral rigosertib extend time
develop secondari md allow patient doctor potenti explor
therapeut option oral rigosertib line iv rigosertib line
could attract potenti partner treat spectrum md
lung cancer ras-driven opportun rigosertib dr rajwanth
veluswami larg portion lung cancer kra mutat specif
adenocarcinoma adeno make lung cancer plan studi
tumor shut part cell respons kra associ
regul hla tumor antigen present two problem caus
kra may solvabl rigosertib rigosertib via disrupt kra signal
induc regul also increas antigen present overal
increas io sensit observ support preclin studi
next trial investig initi
click full note
rizaport migrain pdufa near alzheim
program non-amyloid move forward pipelin
intelgenx report result revenu net loss
compani end period cash balanc
sheet runway
catalyst ahead come week rizaport pdufa rizaport
versafilm formul merck nr maxalt triptan drug use
treat migrain drug gener peak maxalt revenu
despit generic given uniqu deliveri technolog
versafilm expect intelgenx commerci partner gensco pharma
privat price competit
cannabis-infus film move along partner tilray tlri nr
product expect compani await anticip amend
regul around type product canadian regul
alzheim diseas wake nr
aducanumab focu view shift toward non-amyloid base
approach ad could add intelgenx discuss
compani leukotrien receptor agonist monteleukast
conclus pdufa come soon pipelin progress ad
cannabi see catalyst ahead drive higher
rizaport pdufa rizaport versafilm formul rizatriptan benzoat
receptor agonist migrain rizatriptan oral triptan class molecul
constrict blood vessel brain reliev swell symptom
migrain rizaport complet success bioequival studi
refer drug maxalt-mtl us maxalt-lingua eu rizaport nda
accept review fda pdufa intelgenx partner
gensco pharma privat market rizaport us us world largest
migrain market activ drug rizaport use treat symptom migrain
migrain space activ particularli around prophylaxi side therapi
monoclon antibodi ajovi teva teva hold emgal lilli nr
montelukast versafilm phase trial montelukast leukotrien receptor agonist
asthma reduc lung inflamm howev effect may reduc brain
inflamm key driver nbd random studi patient mild
moder alzheim diseas ad underway patient random
receiv either mg montelukast versafilm placebo given daili week
primari endpoint improv neuropsycholog test batteri
composit measur baselin week dsmb review expect
occur first complet week treatment unmet need ad
recent news nr aducanumab trial
halt futil aducanumab target amyloid beta amyloid-beta hypothesi
roch rhhb nr crenezumab lili nr solanezumab three
disappoint follow adacanumab focu ad shift non-amyloid
base drug develop see note link
model chang oper expens around increas line
current burn rate assumpt around rizaport push
tadalafil metric roll forward chang
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
